Core Viewpoint - The investment outlook for the pharmaceutical and bioproducts industry in 2026 indicates a potential recovery in demand and improvement in fundamentals and valuations, particularly in the traditional Chinese medicine sector [1] Group 1: Traditional Chinese Medicine - Short-term pressure from the base is expected to ease, with channel inventory clearing accelerating [1] - There is optimism for demand recovery by the end of the year, along with opportunities for fundamental and valuation improvements [1] - The brand extension space for traditional Chinese medicine consumer companies is broad, supported by innovation [1] Group 2: Blood Products - Attention is drawn to the "14th Five-Year Plan" for plasma station construction and industry consolidation progress [1] - Demand for immunoglobulin and factor products is expected to increase, along with new product development [1] Group 3: Vaccine Industry - Focus on the sales improvement of key products and the progress of innovative pipelines [1] - Policy developments and international expansion of vaccines are anticipated to further drive corporate growth [1] Group 4: Pharmaceutical Retail - The transformation and reform in the pharmaceutical retail sector are progressing steadily [1] - Future catalysts for growth are being monitored [1] Group 5: Pharmaceutical Distribution - The revenue side of the pharmaceutical distribution industry is showing steady improvement [1] - Attention is on payment collection and the "14th Five-Year Plan" [1]

疫苗：经营持续承压，期待销售环比改善及新品贡献 1)看好创新品种未来格局，建议关注创新疫苗管线研发进展。2)政策方面：近期商业保险、医防融合及 行业并购相关政策陆续出台，为疫苗行业未来发展奠定了政策基础，期待后续进展。3)疫苗行业出海： 随着疫苗企业出海事业持续推进，出海动作也在价值链上下游加速延展深化，期待各企业海外市场开拓 进展。4)国资入主持续赋能，关注后续进展。 医药零售：转型变革稳步推进，关注多元催化 智通财经APP获悉，中信建投发布研报称，中药行业短期基数压力有望缓解，渠道库存加速出清，看好 年底需求回暖，及后续基本面和估值改善机会;创新领域有助构建第二增长曲线，中药消费品公司品牌 延展空间广阔。血制品行业关注"十五五"浆站建设规划及行业并购整合进展，需求端看好静丙、因子类 产品需求端提升及新品研发。疫苗行业关注重磅产品销售改善情况及创新管线研发进展，政策出台及疫 苗出海有望推动企业进一步发展。医药零售行业转型变革稳步推进，关注后续多元催化。医药流通行业 收入端稳健向好，关注回款及"十五五"规划。 中信建投主要观点如下： 中药：着眼长期，静待改善 1)短期行业基数压力有望逐步缓解，渠道调整加速出清 ...

Report Investment Rating - No investment rating information provided in the report Core View - The market expects the stock index to continue its long - term and steady upward trend. The 14th Five - Year Plan focuses on technology, and the technology sector is a long - term direction. The domestic liquidity environment is expected to remain loose, with residents likely to increase their allocation of equity assets, and external funds may flow in as the Fed cuts interest rates and the RMB appreciates. Near the end of the year, funds are relatively cautious, and the market style is more balanced compared to the third quarter [2] Summary by Directory 1. Stock Index Futures Market - **IF Contracts**: The previous day's closing prices of IF contracts (current month, next month, next quarter, and the quarter after next) were 4583.40, 4565.20, 4532.20, and 4489.00 respectively, with increases of 23.40, 22.20, 20.00, and 21.20, and increases of 0.51%, 0.49%, 0.44%, and 0.47% respectively. The trading volumes were 25910.00, 76820.00, 14405.00, and 5478.00, and the open interests were 29702.00, 156324.00, 67558.00, and 18583.00, with changes of - 3947.00, - 2502.00, - 388.00, and 316.00 respectively [1] - **IH Contracts**: The previous day's closing prices of IH contracts were 3018.00, 3011.00, 3006.40, and 2996.20 respectively, with increases of 17.40, 16.60, 15.60, and 13.60, and increases of 0.58%, 0.55%, 0.52%, and 0.46% respectively. The trading volumes were 8705.00, 36365.00, 6657.00, and 1812.00, and the open interests were 9339.00, 61909.00, 18559.00, and 5430.00, with changes of - 1795.00, - 1076.00, 283.00, and 134.00 respectively [1] - **IC Contracts**: The previous day's closing prices of IC contracts were 7116.60, 7054.80, 6875.40, and 6664.00 respectively, with changes of - 15.60, - 1.60, 0.40, and - 9.60, and changes of - 0.22%, - 0.02%, 0.01%, and - 0.14% respectively. The trading volumes were 24997.00, 83682.00, 17690.00, and 6223.00, and the open interests were 21873.00, 141911.00, 61676.00, and 23052.00, with changes of - 9350.00, 2214.00, 1590.00, and 39.00 respectively [1] - **IM Contracts**: The previous day's closing prices of IM contracts were 7390.40, 7298.20, 7068.80, and 6838.60 respectively, with changes of - 38.60, - 31.00, - 26.60, and - 28.20, and changes of - 0.52%, - 0.42%, - 0.37%, and - 0.41% respectively. The trading volumes were 37059.00, 149890.00, 27892.00, and 12626.00, and the open interests were 34672.00, 201080.00, 85839.00, and 42548.00, with changes of - 10135.00, 11495.00, - 716.00, and 1475.00 respectively [1] - **Inter - month Spreads**: The current inter - month spreads of IF, IH, IC, and IM were - 18.20, - 7.00, - 61.80, and - 92.20 respectively, compared to previous values of - 14.60, - 6.00, - 73.00, and - 93.80 [1] 2. Stock Index Spot Market - **Major Indexes**: The previous day's values of the CSI 300, SSE 50, CSI 500, and CSI 1000 indexes were 4588.29, 3020.35, 7122.75, and 7387.21 respectively, with changes of 0.44%, 0.58%, - 0.40%, and - 0.82% respectively. The trading volumes (in billions of shares) were 172.92, 48.20, 162.79, and 238.39, and the total trading amounts (in billions of yuan) were 3852.30, 995.51, 2567.55, and 3671.73 [1] - **CSI 300 Industry Indexes**: The previous day's values of different CSI 300 industry indexes showed various changes. For example, the energy, raw materials, and telecommunications sectors had increases of 2.48%, 2.54%, and 1.08% respectively, while the main consumption, pharmaceutical, and IT sectors had decreases of - 0.33%, - 0.65%, and - 0.60% respectively [1] 3. Futures - Spot Basis - **CSI 300 Basis**: The previous day's basis values of IF contracts (current month, next month, next quarter, and the quarter after next) relative to the CSI 300 were - 4.89, - 23.09, - 56.09, and - 99.29 respectively [1] - **SSE 50 Basis**: The previous day's basis values of IH contracts relative to the SSE 50 were - 2.35, - 9.35, - 13.95, and - 24.15 respectively [1] - **CSI 500 Basis**: The previous day's basis values of IC contracts relative to the CSI 500 were - 6.15, - 67.95, - 247.35, and - 458.75 respectively [1] - **CSI 1000 Basis**: The previous day's basis values of IM contracts relative to the CSI 1000 were 3.19, - 89.01, - 318.41, and - 548.61 respectively [1] 4. Other Domestic and Overseas Indexes - **Domestic Indexes**: The previous day's values of the SSE Composite Index, Shenzhen Component Index, SME Board Index, and ChiNext Index were 3946.74, 13080.09, 7943.55, and 3076.85 respectively, with changes of 0.18%, 0.00%, - 0.18%, and 0.25% respectively [1] - **Overseas Indexes**: The previous day's values of the Hang Seng Index, Nikkei 225, S&P 500, and DAX Index were 25830.65, 48702.98, 6642.16, and 23204.14 respectively, with changes of - 0.38%, - 3.22%, 0.38%, and 0.13% respectively [1] 5. Macroeconomic Information - **China - Japan Relations**: China has notified Japan of the suspension of Japanese aquatic product imports. Japan's wrong remarks on Taiwan have damaged the political foundation of China - Japan relations, and China will take counter - measures if necessary [2] - **Domestic Policies**: Deputy Premier Zhang Guoqing emphasized the digital and intelligent transformation of the manufacturing industry and the innovation and development of state - owned enterprises. The National Immigration Administration has expanded the number of ports issuing one - time Taiwan Resident Permits to 100. Russia will implement a visa - free policy for Chinese citizens soon. The Beijing - Tianjin - Hebei region has signed a cooperation plan for the entire industrial chain of free trade zones [2] 6. Industry Information - **Real Estate**: The cumulative sales volume of second - hand homes in key cities increased slightly in the first 10 months of this year, with market activity declining in October. The sales volume in November is expected to recover month - on - month but face pressure year - on - year, and prices may continue to adjust [2] - **Organic Silicon**: The organic silicon industry is discussing production cuts, which are expected to be implemented gradually in early December [2] - **Vaccine Industry**: The China Vaccine Industry Association has issued an initiative against "involution - style" competition to maintain market price stability [2] - **Photovoltaic and Energy Storage**: The 8th China International Photovoltaic and Energy Storage Industry Conference issued the "Chengdu Declaration" to promote capacity structure optimization and industry self - regulation [2] - **Memory Market**: Due to a shortage of key chips, memory prices are expected to rise by about 50% by the second quarter of 2026, with traditional LPDDR4 at the highest risk of price increases [2] 7. Stock Index Views - **Market Performance**: The three major US indexes rose. The previous trading day saw a divergence in the stock index, with the non - ferrous metals and petrochemical sectors leading the gains and the comprehensive and real estate sectors leading the losses. The market trading volume was 1.74 trillion yuan. On November 18, the margin trading balance increased by 2.581 billion yuan to 2.484901 trillion yuan [2]

Group 1: Market Overview - A-shares indices opened higher with the Shanghai Composite Index up 0.35%, Shenzhen Component Index up 1.03%, and ChiNext Index up 1.79% [1] Group 2: Institutional Insights - Huatai Securities continues to recommend cyclical sectors such as aviation, oil transportation, and road infrastructure, citing improved industrial production and export conditions, as well as a moderate recovery in consumer data [2] - The aviation sector is expected to see continued recovery in revenue levels due to low supply growth, industry self-regulation, and a low base effect [2] - The oil transportation sector is anticipated to maintain high prosperity driven by multiple factors including OPEC+/Americas production increases and low oil prices [2] - The road infrastructure sector is seen as having upward potential due to attractive dividend yields and increased insurance fund allocations [2] Group 3: Industry Focus - CITIC Construction Investment is optimistic about the traditional Chinese medicine industry, expecting demand to recover by year-end and improvements in fundamentals and valuations [3] - The blood products sector is highlighted for its focus on the "14th Five-Year Plan" for plasma station construction and industry consolidation [3] - The vaccine industry is monitored for sales improvements of key products and progress in innovative pipelines, with policies and international expansion expected to drive further development [3] - The pharmaceutical retail sector is undergoing steady transformation, with attention on multi-faceted catalysts for growth [3] - The pharmaceutical distribution sector shows stable revenue growth, with a focus on receivables and the "14th Five-Year Plan" [3]

Market Overview - The market experienced narrow fluctuations yesterday, with both the Shanghai Composite Index and the ChiNext Index closing in the green. The total trading volume in the Shanghai and Shenzhen markets was 1.73 trillion, a decrease of 200.2 billion compared to the previous trading day [1]. Sector Performance - The sectors that saw the highest gains included precious metals, military industry, and aquaculture, while sectors such as Hainan, gas, and film and television box office experienced declines. By the end of the trading day, the Shanghai Composite Index rose by 0.18%, and the ChiNext Index increased by 0.25% [1]. Investment Recommendations Huatai Securities - Huatai Securities continues to recommend cyclical aviation, trading in oil transportation, and allocation in highways. The firm notes that external uncertainties have settled, leading to a recovery in industrial production and export sentiment, along with a mild rebound in consumer data. Specifically, they expect: 1. Aviation: October ticket prices continue to improve, supported by low supply growth and a low base, indicating a sustained recovery in industry profitability. 2. Oil Transportation: Multiple favorable factors, including OPEC+/U.S. production increases and low oil prices, are expected to maintain high activity levels in the oil transportation sector. 3. Highways: With insurance funds beginning year-end allocations, the highway sector is anticipated to have upward potential due to attractive dividend yields [2]. CITIC Securities - CITIC Securities is optimistic about the traditional Chinese medicine industry, anticipating a recovery in demand by year-end and subsequent improvements in fundamentals and valuations. They highlight: - The easing of short-term base pressure and accelerated channel inventory clearance. - The potential for innovative areas to create a second growth curve, with significant brand extension opportunities for Chinese medicine consumer goods. - Attention to the blood products sector regarding the "14th Five-Year Plan" for plasma stations and industry consolidation, as well as the vaccine sector's product sales and innovation pipeline [3]. Tianfeng Securities - Tianfeng Securities suggests focusing on the recovery opportunities in the liquor sector, noting a "volume increase, price drop" trend during the 2025 Double Eleven shopping festival. Key points include: - Traditional e-commerce platforms saw major liquor prices fall below critical levels due to inventory pressures, while emerging channels like instant retail and Douyin experienced growth. - Liquor companies are actively combating counterfeiting and stabilizing prices through authorized and unauthorized listings. - The industry is shifting from price wars to value reconstruction, emphasizing high-quality products and refined channel operations. The current dividend returns from leading liquor companies are attractive, and consumer spending is expected to gradually recover [4].

Group 1: Aviation Sector - The aviation industry is expected to continue its recovery trend in ticket prices due to low supply growth, industry self-regulation, and a low base effect [1] - The overall revenue levels in the aviation sector are anticipated to improve [1] Group 2: Oil Transportation Sector - The oil transportation sector is projected to maintain high prosperity driven by multiple factors including OPEC+/U.S. production increases, cross-regional price arbitrage, low oil prices boosting inventory replenishment, and geopolitical disturbances [1] Group 3: Highway Sector - The highway sector is expected to have upward potential as insurance funds begin year-end allocations, and the market's risk appetite experiences fluctuations [1] - The attractive dividend yields of AH highway stocks contribute to the sector's appeal [1] Group 4: Liquor Industry - The liquor industry is experiencing a "volume increase, price drop" phenomenon, with traditional e-commerce platforms seeing prices fall below critical levels due to dealer inventory pressures and platform subsidies [2] - Emerging channels like instant retail and Douyin are showing growth, indicating a shift in consumer purchasing behavior towards "buy now, drink now" [2] - Major liquor companies are initiating anti-counterfeiting actions to stabilize prices and balance online and offline channel interests [2] Group 5: Traditional Chinese Medicine Sector - The traditional Chinese medicine industry is expected to see demand recovery by year-end, with inventory levels clearing up [3] - There are opportunities for fundamental and valuation improvements in the sector [3] - The innovation sector is seen as a potential second growth curve for traditional Chinese medicine companies [3] Group 6: Blood Products and Vaccine Industries - The blood products sector is focused on the "14th Five-Year" plan for plasma station construction and industry consolidation [3] - The vaccine industry is monitoring sales improvements of key products and progress in innovative pipelines, with policies and international expansion expected to drive further development [3]

Group 1: Aviation and Transportation - The aviation sector is expected to continue its recovery due to improved ticket prices in October, low supply growth, and a low base effect [1] - The oil transportation sector is anticipated to maintain high prosperity driven by multiple factors including OPEC+ production increases, cross-regional price arbitrage, and geopolitical events [1] - The highway sector shows potential for upward movement as insurance funds begin year-end allocations, and highway stocks offer attractive dividend yields [1] Group 2: Alcohol Industry - The white liquor industry is experiencing a "volume increase and price drop" phenomenon, with traditional platforms seeing prices fall below key thresholds due to inventory pressures [2] - Emerging retail channels are growing, indicating a shift in consumer behavior towards immediate consumption [2] - The industry is advised to transition from price wars to value reconstruction, focusing on high-quality products and refined channel operations [2] Group 3: Traditional Chinese Medicine and Pharmaceuticals - The traditional Chinese medicine sector is expected to see demand recovery by year-end, with inventory pressures easing [3] - The blood products industry is focusing on the "14th Five-Year" plan for plasma stations and industry consolidation, with increased demand for specific products [3] - The vaccine sector is monitoring sales improvements and innovation pipeline developments, with policies and international expansion likely to drive growth [3]

Group 1 - The short-term pressure on the traditional Chinese medicine industry is expected to ease, with channel inventory clearing accelerating, leading to a positive outlook for year-end demand recovery and subsequent fundamental and valuation improvement opportunities [1] - The innovative sector is expected to help build a second growth curve, with significant brand extension potential for traditional Chinese medicine consumer companies [1] - In the blood products industry, attention is focused on the "14th Five-Year Plan" for plasma station construction and industry merger and acquisition progress, with an optimistic view on the demand for immunoglobulin and factor products, as well as new product development [1] Group 2 - In the vaccine industry, the focus is on the sales improvement of key products and the progress of the innovation pipeline, with policy implementation and international expansion expected to further drive corporate development [1] - The transformation and reform in the pharmaceutical retail industry is steadily advancing, with attention on subsequent multi-faceted catalysts [1] - The pharmaceutical distribution industry shows stable revenue growth, with a focus on receivables and the "14th Five-Year Plan" [1]

机构认为，市场长期震荡上行趋势仍有望延续。 【财经日历】 中国11月LPR 2025世界计算大会（长沙，11/20-11/21） 甲骨文涨2.3%，特斯拉涨0.7%，苹果涨0.4%，亚马逊涨0.1%，Meta跌1.2%，微软跌1.3%。 2025中国锂产业发展大会（厦门，11/20-11/22） 网易发布财报 | (ス) 盘前必读 | // 外盘怎么样 // | | | --- | --- | --- | | 名称 现价 涨跌 | | 涨跌幅 | | 道琼斯工业平均 | | 0.10% | | 22564.23c 131.38 = 纳斯达克指数 | | 0.59% | | 标普500 | 6642.16 24.84 0.38% | | 当地时间周三，美股三大指数集体收涨，截至收盘，道指涨0.10%，标普500指数涨0.38%，纳指涨0.59%。 明星科技股普涨，谷歌涨2.8%并创下历史新高。这得益于市场对其新一代人工智能模型 Gemini 3 的乐观预期，该模型已于周二推出。 芯片巨头英伟达涨近3%。公司于盘后发布的财报显示，营收和盈利均超出华尔街预期，并给出强劲的四季度营收指引。盘后大涨超5%。 热门中概股 ...

2025.11. 19 本文字数：1294，阅读时长大约2分钟 作者 | 第一财经 林志吟 从去年以来，一些疫苗价格战愈演愈烈，已引发业界担忧。 11月19日下午，引导行业持续健康发展，中国疫苗行业协会发布了《关于反对"内卷式"竞争促进疫 苗及其相关生物制品行业高质量发展的倡议》，旨在助力行业打破"内卷"，构建健康有序的良性生 态。 中国疫苗行业协会表示，该倡议经理事会批准后，全体会员应共同遵守，并接受行业与社会监督。如 有违反，将受到全体会员的集体谴责，该协会将给予其警告、通报批评、暂停行使会员权利直至除名 等措施。 根据中国疫苗行业协会官网介绍，现有会员单位330余家，分支机构35个，涵盖我国主要疫苗企业与 生物制品企业，以及为疫苗及生物制品研发、生产、流通配套服务的上下游企业，贯穿生物制药全产 业链和不同业务领域。 在上述倡议出台的背后，从去年以来，在公费市场，一些疫苗价格持续下探。 比如今年9月，在2025年北京流感疫苗免疫类和非免疫类招标采购项目中，上海生物制品研究所的三 价流感疫苗中标价5.5元/支，再度创下公费流感疫苗市场的价格新低。 这也是今年以来国产三价流感疫苗在地方政府采购中第三次刷出历史 ...